News

These patented 200ml ready-to-use (RTU) intravenous bags contain 40mg of the calcium channel blocker nicardipine hydrochloride (0.2mg/ml) in either dextrose or sodium chloride. Previously, the company received the

The designation is based on GenVec having ‘provided evidence of the potential to improve survival in patients with pancreatic cancer’. Fast track designation does not apply to a

According to the company, validation of the patent is currently underway in other European countries. The patent also has been granted in countries outside of Europe and is

Using artida’s real-time, multi-planar reformatting capabilities, physicians can assess global and regional LV function, including volumetric LV ejection fraction. Arbitrary views of the heart, not available in 2D

Under the terms of the multi-year agreement, which is non-exclusive and retroactive, the undisclosed partner will gain access to the internal ribosome entry site (IRES) technology for use

Avrio Biopharma will provide a full range of formulation development and aseptic fill-and-finish services. It will be focused on developing optimized production processes and providing dependable filling, lyophilization

The Extend clinical trial is a Phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin’s lymphoma who received two or more prior therapies and who

This open-label Phase II single-arm study is enrolling patients with stage IIIB or IV non-small cell lung cancer. Approximately 40 patients are expected to be enrolled. This study

In a prospective study called Icare, 2,241 individuals with diabetes mellitus age 55 or over from 47 primary-care clinics in Israel underwent haptoglobin (Hp) genotype testing and were